Innovation
Shining a light on the treatment of CNS disorders and cancer care.
SK Life Science is here listening to the needs of healthcare providers, patients, caregivers, advocates, and scientists. We are developing new molecules, enhancing advocacy efforts, and providing solutions that change what’s possible in the treatment of CNS disorders and cancer care.
Our Medicines
SK Life Science is committed to accelerating the development of next generation treatments for CNS disorders and cancer care. SK Biopharmaceuticals and SK Life Science independently developed XCOPRI® (cenobamate tablets) CV from inception through FDA approval.
For More Information
- XCOPRI Website
- XCOPRI Medication Guide
- XCOPRI Prescribing Information
- SK Life Science Navigator Program for Patient Access
The two companies also discovered and licensed-out the FDA and EMA-approved treatment for sleep disorders after completing phase 1 clinical trials.
U.S. Patent Rights For Products
This website is provided to satisfy the virtual patent marking provisions of the United States, including relevant provisions of the America Invents Act and 35 U.S. Code 287 (a).
The following products are protected by the associated U.S. patents set forth in the table below. The list is subject to change due to issuance of additional patents, product changes and other circumstances. The absence of a U.S. Patent number from the list does not constitute a waiver of the patent, trademark, or other intellectual property rights pertaining to the product.
- XCOPRI®
(cenobamate tablets) CV
U.S. Patent No. 7,598,279
U.S. Patent No. 11,654,133
For Healthcare Providers
Changing What’s Possible
For the latest scientific and clinical information about our medicines, please visit our medical information website. This resource provides up-to-date access to company-sponsored publications and recent medical conference presentations, helping you support your patients in leading healthier and happier lives.
For medical information inquiries on our medicines or to report adverse effects, please email us at Medicalinfo@SKLSI.com or call 1-866-OKSKLSI (657-5574).
Global Patient Safety
Ensuring the safety of patients is our top priority.
We do this through pharmacovigilance monitoring. For more information, please see here.
Our Clinical Trials
We are committed to conducting diverse, global clinical trials. With a commitment to safety, we place our patients at the center of everything we do.
To address the needs of people living with a central nervous system (CNS) disorder, we are currently enrolling patients in the following clinical trials:
- Global Primary Generalized Tonic-Clonic (PGTC) Seizures Clinical Trial: Our global Phase 3 trial has sites in the U.S. as well as in Australia, Hungary, Poland, Slovakia, South Korea, and Spain. Other locations will be available soon. The trial is recruiting pediatric patients between the ages of 12 and 17. For more information, please visit www.PGTCSeizureStudy.com. If you are a healthcare professional and would like to receive more information, please contact us via email at cenobamatePGTC@sklsi.com.
- Global Pediatric Clinical Trials: We are currently enrolling in two studies for pediatric patients diagnosed with partial onset seizures. For more information, please visit www.FocalSeizureStudy.com.
- Phase 1 Open Label Pharmacokinetics Study: This study is currently recruiting patients between the ages of 2 and 5. The trial is recruiting in the U.S. as well as in South Korea.
- Phase 3 Open Label Safety Study: This study is currently recruiting patients between the ages of 4 and 5. The trial is currently recruiting in the U.S. as well as in Australia, Hungary, Poland, South Korea, and Spain.
- Phase 1 Open Label Pharmacokinetics Study: This study is currently recruiting patients between the ages of 2 and 5. The trial is recruiting in the U.S. as well as in South Korea.
- Global LGS DISCOVER Study: The LGS DISCOVER study is evaluating whether an investigational medicine can decrease the number of seizures in patients 4-55 years of age living with Lennox-Gastaut syndrome. The trial is currently recruiting in Australia, Colombia, Hungary, Germany, Greece, Italy, Korea, Mexico, Poland, Portugal, Serbia, Spain, Taiwan, and the U.S. For more information, please visit www.LGSDiscoverStudy.com.
*Other locations may be available soon, so please check back regularly.
Our Global Pipeline
SK Life Science and its parent company SK Biopharmaceuticals have 8 compounds under development globally.
| Compound | Indication |
Phase 1
Phase 2
Phase 3
|
|---|---|---|
| Cenobamate |
Epilepsy
Focal (partial) – Onset Seizures1 (Asia)
|
|
|
Epilepsy
Primary Generalized Tonic-Clonic Seizures
|
||
| Carisbamate |
Lennox-Gastaut Syndrome
|
|
| Relenopride |
Rare Neurological Disease
|
|
| SKL24741 |
Epilepsy
|
|
| SKL20540 |
Schizophrenia
|
|
| SKL27969 |
Advanced Solid Tumors
|
|
| SKL13865 |
Attention Deficit / Hyperactivity Disorder
|
|
| SK-PSY |
Bipolar Disorder
|
* Partnership
1 In 2020, SK Biopharmaceuticals, the parent company of SK Life Science, initiated a clinical development program for cenobamate in China, Japan and Korea
Invigorating Next Generation Discovery
We are a group of scientists, inventors, and explorers tirelessly working to develop solutions that will improve CNS and cancer care
Leveraging Technologies to Include:
- Target-based drug discovery techniques
- High throughput organic screening (HTOs)/high content screening (HCS)
- Computer-aided drug design (CADD)
- Combinatorial chemistry
Key R&D Sectors:
We deploy our technologies in the areas of biology/discovery, medicinal chemistry, and pharmacology. The goal of research in these areas is to bring meaningful products to market.
Select A Sector For Details
We are responsible for lead compound discovery and optimization. This sector:
- IDENTIFIES and validates signal and molecular targets
- DEVELOPS screening technologies
- PERFORMS high-throughput screening (HTS) leveraging technologies
- PARTICIPATES in joint studies on targets known to have high target-disease correlation
- INVESTIGATES the efficacy and safety of lead compounds
The medicinal chemistry sector of SK Life Science is responsible for:
- IDENTIFYING a wide array of drug candidates for the treatment of CNS disorders and cancer
- OPTIMIZING lead compounds in terms of their structure-activity relationships
- DEVELOPING processes for clinical candidates to lead compound discovery and optimization
To maximize efficiency, we have implemented a CADD system, a high-efficiency synthesis infrastructure, an established structure-diverse library, and a target focus library.
The pharmacology sector is responsible for research programs in which drug candidates are studied to enable prediction of drug activity in the human body.
Grant Requests
Medical Education Grant Request
Please complete and return the Medical Education Grant Request form and the outlined documents to request a Medical Education Grant. Grant requestors will be notified within 30 days of submission. The documents listed in the form must be submitted to Grants@SKLSI.com, along with a completed Medical Education Grant Request form.
Investigator Initiated Study Proposal Procedure
All requested information must be submitted to Grants@SKLSI.com. Decisions are made based on medical and scientific merit as well as available budget.
Following the Submission:
- SK Life Science will acknowledge receipt of all Investigator Initiated Study (IIS) proposals via email.
- The IIS Committee will review the request to determine SK Life Science initial interest in the proposal.
- If the IIS Committee has interest in the proposal, the submitter will need to provide certain documents, including a full protocol, which will be reviewed by the IIS Committee.
- A formal notification of the outcome of the review will be sent via email.
Expanded Access & Compassionate Use
Please click on the below button to learn more about SK Life Science’s Expanded Access and Compassionate Use policy.
Transparency
Vermont State Regulations
Long form disclosure for XCOPRI® (cenobamate tablets) CV
Short form disclosure for XCOPRI® (cenobamate tablets) CV